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Abstract: The class 1 PI3Ks are lipid kinases with key roles in cell surface receptor-triggered signal transduction 
pathways. Two isoforms of the catalytic subunits, p110 and p110, are enriched in leucocytes in which they promote 
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Genetic inactivation or pharmaceutical inhibition of these PI3K isoforms in mice result in impaired immune responses and 
reduced susceptibility to autoimmune and inflammatory conditions. We review the PI3K signal transduction pathways and 
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OVERVIEW 
 The inflammatory response is a complex and highly 
regulated consequence of stimuli received from pathogens or 
damaged cells. Inflammation is triggered by bacterial 
derivatives (e.g. LPS or fMLP), molecules released from 
damaged cells (e.g. ATP) and chemical mediators (such as 
complement) which activate resident cells of the innate 
immune system to engulf pathogens and release pro-
inflammatory cytokines to recruit leucocytes to the inflamed 
tissue. Subsequently, T and B lymphocytes participate in a 
targeted and specific response following presentation of 
pathogen-derived or disease associated antigens [1]. 
 This powerful system is critical for defence against 
pathogens. The severe and often lethal phenotypes exhibited 
by patients with defects in immune cell function illustrate all 
too clearly the importance of immune system integrity. 
However this essential system has great potential to harm the 
host. Lymphocytes gain tolerance to host tissues through 
clonal deletion, anergy or via suppression by regulatory T 
cells. When these processes fail autoreactive lymphocytes 
can cause autoimmune and inflammatory conditions, often 
resulting in significant morbidity  [2, 3]. 
 The diverse roles served by PI3K in the innate and 
adaptive immune system offer hope that inhibition of this 
axis may provide new treatments for autoimmune conditions  
[4]. The ultimate goal must be to alleviate pathological 
inflammation while leaving resistance to infection intact. In 
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this review we discuss the current understanding of class 1 
PI3K signal transduction, with a particular focus on the PI3K 
isoforms p110 and p110 which are enriched in leucocytes. 
We examine how targeting these isoforms shows promise as 
a therapeutic strategy in autoimmunity, focussing on two 
systemic rheumatic diseases, rheumatoid arthritis (RA) and 
systemic lupus erythematosus (SLE), but also allude to other 
immune-related conditions that may be treated using PI3K 
inhibitors. 
PHOSPHOINOSITIDE 3-KINASES 
 Phosphoinositide 3-kinases (PI3Ks) are lipid kinases that 
phosphorylate the 3-hydroxyl position of the inositol ring of 
phosphatidylinositol (PI) substrates within the plasma 
membrane and intracellular compartments. These substrates 
comprise PI, phosphatidylinositol-4-phosphate (PIP) and 
phosphatidylinositol-4,5-bisphosphate (PI-4,5-P2). The 
phosphorylated effector products recruit and activate 
proteins expressing the lipid-binding Pleckstrin Homology 
(PH), phox homology and FYVE domains. PI3Ks control a 
wide variety of cellular processes, including migration, 
proliferation, differentiation and vesicular trafficking  [5-7]. 
 PI3Ks are classified according to their sequence 
homology and substrate specificity. Class I PI3Ks convert 
PI-4,5-P2 into PtdIns-3,4,5-triphosphate (PIP3), class II 
PI3Ks convert PI-4-P into PI-3,4-P2 and PI into PI-3-P, while 
the class III PI3K converts PI into PI-3-P. Class I PI3Ks are 
the most extensively studied and form the principle focus of 
this review. The biological functions of Class II PI3Ks are 
less well understood; the single class III PI3K enzyme 
Vacuolar Protein Sorting 34 (VPS34) is involved in vesicular 
intracellular trafficking and autophagy (Table 1). 
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 PI3Ks have diversified throughout evolution: yeast have 
only a class III PI3K enzyme, Caenorhabditis elegans and 
Drosophila melanogaster have single isoforms of each of the 
class I, II and III enzymes, while mice and humans have four 
class I isoforms, three class II isoforms and one class III 
PI3K  [8]. 
 The class 1A PI3K enzymes are heterodimers comprised 
of a regulatory subunit (p85) and a catalytic subunit (p110). 
Five regulatory Src Homology 2 (SH2) domain containing 
subunits have been identified; p85, p50, andp55, (from 
alternative transcripts encoded by the Pik3r1 gene), 
p85 (encoded by Pik3r2), and p55 (encoded by Pik3r3). 
Each of these regulatory subunits associates with any one of 
three catalytic subunits, p110, p110 and p110. Class 1A 
PI3K regulatory subunits contain SH2 domains which enable 
recruitment to tyrosine phosphorylated proteins at the plasma 
membrane, thus receptor tyrosine kinases (RTKs) form their 
principle means of activation. The p110 catalytic subunit 
associates with either p101 or p87/p84 to form the class 1B 
PI3K heterodimer which is generally activated by G-coupled 
protein receptors (GPCRs) [5-7]. 
 p110 and p110 are ubiquitously expressed whereas 
p110 and p110 are enriched in leucocytes. p110 is also 
expressed in some neurons  [9] and cancer cell lines  [10], 
but has low expression in other tissues. p110 is expressed in 
cardiac myocytes and plays important roles in cardiac 
physiology, both as a kinase and as an adapter regulating 
cAMP-mediated signalling cascades [11-14]. 
 The preferential signalling through p110 and p110 
isoforms in leucocytes has prompted considerable 
pharmaceutical interest [4]. Targeted inhibition of these 
isoforms should provide immunotherapeutic benefit while 
minimising organ toxicity. Indeed, compounds inhibiting 
p110 are already being assessed in clinical trials for the 
treatment of haematological malignancies [15-18]. Pan-PI3K 
and p110selective inhibitors are being evaluated in 
clinical trials for cancer [19]. 
ACTIVATION OF PI3KS BY TYROSINE KINASE 
AND/OR G PROTEIN COUPLED RECEPTORS 
 PI3K p110 and p110 signalling is initiated by different 
cell surface receptors in different cell types of the immune 
system, transmitting signals promoting growth, activation 
and differentiation. Key signalling cascades are initiated in 
neutrophils, macrophages, dendritic cells, T cells, B cells and 
mast cells (summarised in Fig. 1). 
 All four of the class 1 PI3K's have a Ras binding domain 
(RBD) in their catalytic subunit and the physiological role of 
Ras in PI3K activation has been elucidated by generating 
mice with mutations in the p110 or p110 RBDs. In p110 
signalling, Ras has been shown to contribute to normal 
neutrophil function [20] whereas mice with a mutation in the 
p110 RBD show impaired lymphatic vessel development 
and reduced viability and resistance to Ras oncogene-
induced tumourigenesis [21]. The Ras-related protein TC21 
contributes to basal activation of p110 in B cells and T cells 
and TC21
-/-
 mice show some similarities with p110-
deficient mice [22]. 
 The simple concept that class 1A PI3Ks are activated by 
growth factor and cytokine RTKs and the class 1B PI3K is 
activated by chemokine responsive GCPRs does not always 
hold true. For instance, it is becoming increasingly clear that 
GCPRs can activate a wider range of PI3K isoforms than 
initially thought. p110 can be activated by GPCRs in B 
cells [23] and in natural killer cells [24], and p110 can be 
activated by GPCRs in cells where p110 is not highly 
expressed or when tyrosine kinase and GPCR signals merge 
[25, 26]. Conversely, the p84/p110 heterodimer was shown 
to be activated by tyrosine-kinase linked receptors in 
macrophages by a Ras-dependent mechanism [27]. 
NEGATIVE REGULATION OF CLASS 1 PI3K 
SIGNALLING 
 The PI3K-Akt signalling axis has a profound influence 
on cellular functions, and must therefore be tightly regulated. 
Constitutive activation of class 1 PI3K signalling 
predisposes to autoimmunity and cancer, while inactivation 
of isoforms has varying effects ranging from embryonic 
lethality to immune deficiency, demonstrating the critical 
importance of maintaining physiological balance in this 
cellular cascade. The tight control of PIP3 levels within the 
plasma membrane is controlled by phosphatases including 
PTEN and SHIP which dephosphorylate PIP3 on the D3 and 
D5 positions, respectively. Deletion of SHIP and/or PTEN in 
lymphocytes leads to a variety of autoimmune syndromes 
and leukaemia [28-31]. Interestingly, drugs that activate 
SHIP may be used as anti-inflammatory drugs, presumably 
by inhibiting PI3K signalling in blood cells [32]. 
 
Table 1. Catalytic and Regulatory Subunits of PI3Ks and their Lipid Substrates and Products 
 
 Catalytic Subunit Regulatory Subunits Substrate Product 
Class 1A p110 
p110 
p110 
p85, p85, p55, p55, p50 PI-4,5-P2 PIP3 
Class 1B p110 p101, p84 PI-4,5-P2 PIP3 
Class II PIK3-C2 
PIK3-C2 
PIK3-C2 
 PI-4-P 
PI 
PI-3,4-P2 
PI-3-P 
Class III VPS34 p150 PI PI-3-P 
Note that while there are three different types of PIP2 (PI-3,4-P2, PI-3,5-P2
 and PI-4,5-P2), there is only one kind of PIP3 headgroup (PI-3,4,5-P3), 
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DOWNSTREAM SIGNALLING 
 The phosphorylation of PI-4,5-P2 to PIP3 at the inner 
leaflet of the cell membrane by PI3K permits the activation 
and recruitment of effector proteins expressing PH domains, 
including PDK1, Akt (also known as Protein Kinase B), 
guanine nucleotide exchange factors (GEF), and Tec family 
kinases. The best studied of these is the serine/threonine 
kinase Akt which can phosphorylate a large number of 
substrates [33]. Among these is the mammalian Target of 
Rapamycin mTOR [8] (Fig. 2). Rapamycin-based drugs are 
commonly used immunosuppressants in kidney transplant 
recipients [34]. Although rapamycin has been evaluated as a 
potential therapeutic in RA [35] and SLE [36], the associated 
adverse effects may be too severe for routine use in 
autoimmunity. 
Insights from Mouse Models 
 The interrogation of signalling pathways in which the 
class I PI3Ks play a key role has been facilitated by the 
availability of small molecule inhibitors with high selectivity 
for the various class 1A isoforms and the development of 
mice with inactivating mutations in PI3K genes. These 
strategies provided a considerable advance on earlier 
approaches which utilised wortmannin or LY294002 (pan-
PI3K inhibitors with known off-target effects on class II and 
III PI3K's, mTOR and casein kinase 2) allowing the 
dissection of the contributions of specific PI3K isoforms to 
lymphocyte signalling, trafficking, proliferation and 
development. 
 Homozygous deletion of the gene for p110 or p110 
results in early embryonic lethality [37, 38]. Mice 
homozygous for an inactivating mutation in p110 also die 
as embryos [39], whereas mice with an inactivating mutation 
of p110 are born at reduced Mendelian ratios, yet survive 
into adulthood indicating that an unexpected non-catalytic 
function of p110 partially protects against this mortality 
[25, 26, 40]. 
 By contrast mice with genetic inactivation of p110 or 
p110 are born at normal Mendelian ratios and live a normal 
life span despite having impaired immune cell responses [41-
46]. The burgeoning interest in p110 and p110 as 
therapeutic targets in autoimmunity has been built on 
substantial data emerging from the study of mice with 
genetic and pharmacological inactivation of these isoforms, 
examples of which are detailed in Table 2. 
PI3K IN B CELLS 
 The key role for PI3K in B cell physiology was first 
demonstrated by p85-/- mice which showed impaired B cell 
development and humoral immune responses [93, 94], and 
this phenotype was also seen in mice with p110 deletion or 
inactivation [41, 45, 46]. In particular, mice lacking p85 or 
p110 have markedly reduced B1 cells (self-renewing IgM 
producing B cells populating the pleural and peritoneal 
cavities) and marginal zone B cells, with a lesser reduction 
in follicular B cells. In vivo, both the PI3K isoforms p110 
and p110 contribute to tonic survival signals generated by 
the B cell receptor (BCR) in absence of antigen, whereas 
p110 is preferentially activated by acute BCR signalling 
[75]. Reduced homing to Peyer's patches and splenic white 
pulp cords is seen in adoptively transferred kinase-dead 
p110 B cells, reflecting a role for p110 in B cell 
chemotaxis [23]. Mice lacking p85 or p110 exhibit 
reduced T-independent antibody responses and p110 
inactive B cells have reduced proliferative responses to anti-
IgM, anti-CD40 and interleukin(IL)-4 stimulation  [41, 46, 
67]. Furthermore, TLR9-mediated antibody class switching 
is blocked as a result of p110 inactivation [95]. However, 
p110 signalling also negatively regulates class switch 
recombination through activation-induced cytidine 
deaminase (AID) expression during germinal centre 
responses such that inhibiting p110 can increase class 
switching [68, 69, 96]. 
 Although much is known about the central role played by 
p110 in development and activity of conventional B cells, 
its precise function in the recently described regulatory B 
cell subset has not been reported. Regulatory B cells were 
first identified in mice and subsequently in humans, and 
mediate their regulatory function via the production of IL-10 
[97-99], leading some authors to describe them as B10 cells 
[96]. In humans, IL-10 producers comprise 1-5% of 
Fig. (1). p110 and p110 are involved in the response to various cell signalling cascades that depend on cell type. 
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circulating B cells, although cells with the potential to 
produce IL-10 may be found at higher frequencies. 
Abnormalities in the number [95] or function [99] of 
regulatory B cells have been described in patients with 
autoimmune diseases, suggesting that this subset may be of 
relevance to the development of treatments for 
autoimmunity. 
 Consistent with an important role for PI3K in B cell 
homeostasis, patients with B cell malignancies have 
responded well to the p110-selective inhibitor CAL-101. In 
one study, all chronic lymphocytic leukaemia (CLL) patients 
treated with this inhibitor showed a reduction in lymph node 
size which was often associated with an increase in blood 
lymphoblast count [18]. However, patients who stopped 
taking the drug showed recurrent lymph node enlargement 
suggesting that the drug had not necessarily just killed the 
leukaemia cells - rather, these results raise the possibility that 
p110 is required for stromal cell support of proliferating 
CLL cells, perhaps by virtue of its role in chemokine 
receptor signalling. In vitro studies of the effect of CAL-101 
on CLL cell viability showed that it was able to block the 
pro-survival effect of BCR cross-linking with IgM, as well 
as reducing elevated CCL3 and CCL4 levels [15, 100]. 
Further studies have shown that CAL-101 inhibits CLL cell 
chemotaxis and migration beneath stromal cells and 
sensitises CLL cells toward standard chemotherapeutic 
agents [101]. 
PI3K IN T CELLS 
 p110-deficient mice have relatively normal numbers of 
thymocytes, while p110-deficient mice have a modest 
reduction in numbers [43]. However, combined p110/ 
p110 deficiency has a much more significant impact on 
thymocyte numbers, with substantially reduced transition 
through the CD4
-
CD8
-
 stage and reduced survival of cells at 
the CD4
+
CD8
+
 stage [86, 87]. The apparent redundancy of 
p110 and p110 during T cell development is surprising, 
given that these PI3K isoforms are activated by distinct 
receptors. This conundrum was recently resolved by 
demonstrating a requirement for CXCR4 signalling in the 
thymus which was mostly dependent on p110, whereas pre-
TCR signalling was entirely dependent on p110 [88]. 
Elevated Th2 cytokines and eosinophilia observed in p110-
p110 double deficient mice may well be a consequence of 
impaired T cell development and subsequent lymphopenia 
induced proliferation of the few T cell that do develop [85]. 
 T helper cell differentiation and cytokine production is 
PI3K dependent in mice and humans as demonstrated by the 
ability of p110-selective inhibitors to block IFN-, IL-4 and 
IL-17 indicating that PI3K function is required in 
differentiated T helper cells [71]. Akt and Foxo signalling 
downstream of the TCR and CD28 is attenuated in 
p110D910A mice with impaired differentiation along the Th1 
and Th2 lineages [76] and p110D910A mice exhibited 
significantly decreased Th2 cytokine responses and were 
 
Fig. (2). The production of PIP3 is a critical signalling hub. GPCR's and receptor tyrosine kinases expressing a YxxM motif recruit PI3K to 
the plasma membrane via interactions with SH2 domains. PI3 kinases then catalyse the formation of PIP3 from PI-4,5-P2. PIP3 then acts on a 
variety of downstream effectors expressing PH domains to promote cellular responses. 
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protected against eosinophilic airway inflammation [78]. 
Moreover, p110D910A mice were resistant to experimental 
autoimmune encephalitis which was correlated with reduced 
numbers of Th17 cells [102]. 
 PI3K also plays an important role in T follicular helper 
(TFH) cells, a subset of T cells which are critical for the 
provision of help to germinal centre B cells during affinity 
maturation and for their differentiation into long-lived 
plasma cells [103]. TFH cells are likely to be crucial 
pathogenic mediators in SLE, as it is the long-lived plasma 
cells they create that exhibit most resistance to B cell 
depleting therapies and are the predominant source of high-
affinity pathogenic autoantibodies [104, 105]. The ability of 
the costimulatory ICOS to induce TFH cells and to promote 
the generation of germinal centres and high affinity, class 
switched antibodies is critically dependent on p110 [64, 
106]. 
 Regulatory T cells (Tregs) develop both in the thymus 
and the periphery from mature CD4 T cells and serve a 
critical role in controlling the adaptive immune system and 
preventing unrestrained inflammatory responses [107]. 
p110D910A mice has revealed increased numbers of Tregs in 
the thymus, but reduced numbers in the spleen and lymph 
nodes implicating a role for p110 in the maintenance of 
Tregs in the periphery [79, 108]. p110-inactive Tregs also 
fail to suppress T cell proliferation in vitro, to secrete the key 
suppressive cytokine IL-10 and to prevent a model of 
inflammatory bowel disease [79]. Interestingly, p110-
deficient mice show enhanced clearance of the protozoan 
parasite Leishmania major, despite a major reduction in Th1 
cells [81], in part as a consequence of altered Treg function. 
mTOR deficient T cells display normal activation and IL-2 
production on stimulation, but impaired differentiation into 
Th1, Th2 and Th17 cell subsets; instead T cells differentiated 
into Foxp3+ regulatory T cells [2, 109, 110]. Rapamycin also 
promotes the expansion of Tregs [111]. Moreover, Foxo 
transcription factors control the pivotal transcription factor 
Foxp3 which is both necessary and sufficient for the 
induction of regulatory T cell (Treg) function [112]. PI3K 
signalling can therefore suppress Foxp3 expression by 
activating Akt which phosphorylates and sequesters Foxo1 
and Foxo3a [1]. The ability of PI3K to activate mTOR and 
inhibit Foxo may explain the increased abundance of Tregs 
in the thymus, but does not explain the paucity of Tregs in 
the spleen of p110D910A mice [79, 108]. 
PI3K IN NEUTROPHILS 
 Neutrophils are the most abundant circulating phagocyte 
and form the cornerstone of the innate immune system, 
playing a central role in the destruction of invading 
pathogens [113]. Neutrophil dysfunction is also known to 
contribute to the pathogenesis of a number of autoimmune 
diseases, including SLE and RA. Thus, inhibition of 
neutrophil activation is a potential therapeutic goal in the 
treatment of these conditions and pathways implicated in 
dysfunctional intracellular signalling may provide promising 
routes of enquiry. 
Table 2. Selected Mouse Models of PI3K p110 and p110 Signalling and their Principle Phenotypic Findings (Also Reviewed in 
[90-92]). p110D910A Mice Harbour a Point Mutation Rendering the Kinase Inactive 
 
Model Details Cells /Conditions Studied 
PI3K-/-[42-44] PI3K knock-out T cells [43, 47-50] 
NK cells [24, 51-53] 
Neutrophils [42-44, 54-57] 
Mast cells [58] 
Dendritic cells [59] 
PI3Kcx/cx [60] Constitutively active PI3K Neutrophils and macrophages. 
PI3KKD/KD [12] Kinase-inactive PI3K Neutrophils and macrophages. 
PI3K-/-[45, 46] PI3K knock-out B cells [45, 46, 61-63] 
T cells [45, 64] 
NK cells [51, 53, 65] 
PI3K selective inhibitors 
[66]  
IC87114 B cells [67-69] 
Neutrophils [56, 66, 70] 
T cells [71-73] 
PI3KD910A/D910A [41] Kinase-dead PI3K B cells [41, 67, 68, 74, 75] 
T cells [41, 48, 72, 76-81] 
Mast cells [82, 83] 
Neutrophils [26, 56] 
Dendritic cells [81, 84] 
NK cells [24, 52] 
PI3KKO/D910A [85] 
OR 
PI3K-/--/- [86, 87] 
PI3K knock-out, PI3K kinase-
inactive; 
PI3K and PI3K knock-out. 
T cells [85-88] 
B cells [89] 
NK cells [51] 
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 In common with other leucocytes, the p110  and p110  
isoforms of PI3K are markedly enriched in neutrophils. 
However, although both p110  and p110 are both expres-
sed in neutrophils, the upstream RTKs and GPCRs that 
recruit and activate them are downstream of a markedly 
different array of cell surface receptors to those implicated in 
PI3K signalling in lymphocytes. Integrins, Fc receptors and 
cytokine receptors are key among RTK stimuli, and 
receptors for fMLP, C5a and LTB4 are all known to activate 
GPCR-mediated PI3K activity [114]. 
 Effective neutrophil function is dependent on several 
related activities ranging from chemotaxis, endothelial 
adhesion, diapedesis, phagocytosis, activation, 
phagolysosomal maturation, free radical production and 
(later) apoptosis. Class 1 PI3K control neutrophil spreading 
on endothelium [115], migration [57, 70] and pathogen 
killing [116]. In addition the class 3 PI3K VPS34 is 
important in phagocytosis [117]. 
 PI3K genetic knockout in mice results in fully 
differentiated neutrophils that fail to phosphorylate Akt and 
show impaired respiratory burst, motility and migration 
toward chemotactic stimuli, especially in vivo(42). PI3K 
activity through the p110 isoform can contribute to cell 
polarisation, with PIP3 generation at the leading edge 
involved in actin rearrangement [54, 118]. However an 
important role also exists for SHIP, with SHIP
-/-
 neutrophils 
demonstrating impaired localisation of Akt at the leading 
edge of the plasma membrane reducing motility [108]. 
 In vitro the impairment of neutrophil directional 
movement by p110 inactivation is exacerbated by 
pharmacological inhibition with the p110-specific inhibitor 
IC87114 [66]. A phenotype reproduced in in vivo models of 
pulmonary inflammation and arthritis [119]. The effects on 
neutrophil migration are mediated through both reduced 
neutrophil tethering in TNF- primed blood vessels (p110-
mediated) and via impaired transmigration of neutrophils 
across vessel walls (p110-mediated) [120]. 
 At the site of infection, neutrophils kill pathogens by 
generating reactive oxygen species (ROS) via the respiratory 
burst process. Genetic inactivation of p110 impaired ROS 
production in neutrophils in response to fMLP(42), in 
keeping with a likely impairment in killing of phagocytosed 
pathogens. p110 is also implicated in neutrophil respiratory 
burst in human (but not mouse) neutrophils stimulated with 
fMLP, where initial transient p110-dependent PIP3 
generation is followed by more sustained p110-mediated 
PIP3 production [56]. 
 Neutrophil PI3K signalling is not wholly dependent on 
p110 and p110 as the p110 isoform has also been shown 
to play a critical role in FcR-dependent activation of mouse 
neutrophils by IgG immune complexes. ROS production in 
response to low concentrations of immune complexes is 
completely blocked by p110 inhibition. At higher 
concentrations of immune complexes, combined inhibition 
of p110 and p110 was required to achieve the same 
suppression of ROS. In an in vivo model of FcR-dependent 
inflammatory arthritis, combined p110 and p110 
deficiency provided almost complete protection from 
pathology [26]. 
 The diverse and complementary influences of the various 
isoforms of PI3K on neutrophils suggest that drugs targeting 
p110 and p110 may exert immunosuppressive effects that 
could be of value in conditions in which neutrophil 
activation play a prominent role, and that strategies which 
both target single isoforms and combination inhibition may 
offer therapeutic benefit. Accompanying this potential is the 
concern that PI3K inhibition could increase susceptibility to 
opportunistic infections as suggested by the increased 
susceptibility to Streptococcus pneumoniae pneumonia seen 
in p110-/- mice [121] 
PI3K IN OTHER CELLS OF THE IMMUNE SYSTEM 
 Mast cells reside in tissues such as the skin and mucosa 
and are characterised by the ability to release large amounts 
of heparin and histamine from their cytoplasmic granules. 
This release is mediated by the RTKs c-Kit and FcR1 which 
couple to the p110 isoform of PI3K. Mast cell 
degranulation plays an important role in allergic 
inflammatory disorders such as asthma and allergic rhinitis, 
and in anaphylaxis. Mice with inactive p110 and those 
treated with a pharmacological p110 inhibitor are protected 
from passive cutaneous anaphylaxis [82, 83]. p110 
inhibition and p110-/- mice have normal early mast cell 
responses but a reduced phenotype at later stages, suggesting 
an impairment in signal amplification [58]. 
 Dendritic cells (DCs) are potent antigen-presenting cells 
with roles in initiating cellular and humoral immune 
responses and in tolerance induction. Prior to antigen 
encounter DCs reside in tissues in an immature state, 
becoming activated upon contact with antigen in the context 
of inflammatory or pathogen-derived stimuli. This activation 
leads to DC migration to the T-cell rich paracortex of 
draining lymph nodes where they present antigen to CD4 T 
cells, initiating immune responses. DCs have been studied in 
p110-/- mice, in which they demonstrate normal 
differentiation but have markedly impaired migration. This 
results in a reduction in severity of contact hypersensitivity 
in p110-/- mice [59] and may delay symptoms in an 
experimental autoimmune encephalitis [122]. The role of 
PI3K is not limited to p110; p110 has a key role in 
promoting IL-6 release in response to cKit stimulation on 
dendritic cells by cholera toxin [84]. 
 Macrophages coordinate C5a and FcR signalling 
through the p110 and p110 isoforms of PI3K. In a mouse 
model of the passive reverse lung Arthus reaction, genetic 
deletion of p110 blocked C5aR signalling crucial for 
activation of lung macrophages. However C5a production 
occurred normally in p110-/- mice but was impaired in 
p110-/- mice, which demonstrated resistance to acute 
immune complex-induced lung injury, thus defining p110 
as a crucial element of FcR signalling in the production of 
C5a [123]. 
 Eosinophils infiltrate release pro-inflammatory cytokines 
and ROS in response to IgE immune complexes. Studies 
using the pan-PI3K inhibitor wortmannin have implicated 
PI3K in eosinophil chemotaxis and release from the bone 
marrow [124], and inhibitor-treated mice show a reduction in 
eosinophilia in allergen-induced bronchial inflammation 
[125]. Subsequent studies suggest that p110 is the isoform 
most likely mediating this effect [126, 127]. However, some 
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data suggest that combined PI3K inhibition may also have 
unwanted effects on eosinophils as p110-p110 double-
mutant mice developed marked eosinophilic infiltration in 
multiple organs, with increased serum IgE, IL-4 and IL-5 
[85]. 
PERTURBATIONS OF THE PI3K PATHWAY IN 
RHEUMATIC DISEASES 
Rheumatoid Arthritis 
 RA is characterised by synovitis and systemic 
inflammation secondary to autoantibody production 
(particularly rheumatoid factor and citrullinated peptide). It 
is common, disabling and can have a significant impact on 
patients' quality of life [128]. Current treatment strategies 
centre on the use of disease-modifying antirheumatic drugs 
(DMARDs) as a first line treatment [129-132]. However, 
these are agents are non-specific, may be associated with 
problematic side effects and disease flares occur despite such 
treatments. Advances in RA therapies have been 
considerable in recent years with a number of biological 
agents receiving approval. These include TNF inhibitors 
[133], a CTLA-4 fusion protein (abatacept) [134], a B cell 
depleting CD20 antibody (rituximab) [135] and an IL-6 
inhibitor (tocilizumab) [136]. Although these biological 
treatments have demonstrated impressive efficacy in subsets 
of patients, their widespread use remains limited by cost and 
susceptibility to infection [137]. Furthermore, not all patients 
respond to such treatments. Thus there remains an unmet 
need to develop further targeted therapies that may benefit 
patients with RA. 
 The underlying pathogenesis of RA is complex and can 
involve inappropriate activation of cells of both the innate 
and adaptive immune systems with T cells [138], B cells 
[139], dendritic cells [140], mast cells [141] and neutrophils 
[142] all implicated in disease models and human pathology.
  
 RA is thought to be initiated in peripheral lymphoid 
organs by the presentation of self-antigens to autoreactive T 
cells. This in turn prompts activation of autoreactive B cells 
to produce autoantibodies that form immune complexes. 
These deposit in joints triggering the release of pro-
inflammatory cytokines from neutrophils, macrophages and 
mast cells that cause inflammatory cell migration and pannus 
formation. Tissue damage then results from the activation of 
synoviocytes which invade cartilage and osteoclasts which 
increase bone resorption [143]. Over time irreversible bone 
and cartilage destruction occurs, leading to accrual of 
disability [128]. 
 The p110 and p110 isoforms of PI3K have attracted 
considerable interest as pharmacological targets in the 
treatment of RA given the known effects of their inhibition 
on a variety of immune cells [4] (Table 3). PI3K blockade 
by both genetic and pharmacological approaches suppresses 
joint inflammation and damage in two murine models of RA 
- collagen-induced arthritis (CIA) and CII-induced arthritis 
(CII-IA). In the CIA model mice treated with AS-605240 
(a p110-selective inhibitor) showed a significant reduction 
in joint inflammation with a near normal mean paw 
thickness. There was also marked amelioration of 
histological measures of synovial inflammation, cartilage 
erosion and neutrophil infiltration in arthritic joints. Similar 
findings were observed in the CII-IA model using both 
mice with genetically inactive p110 and pharmacological 
inhibition with the same small molecule inhibitor. Similarly 
p110-deficient and p110 inhibitor treatment ameliorated 
disease in the early stages of antigen-induced arthritis [144]. 
A further role for p110 is seen in the regulation of synovial 
fibroblasts in RA, in which p110 deficiency leads to a 
milder inflammatory erosive arthritis and TNF- mediated 
cartilage destruction. p110 is highly expressed in the 
synovium of patients with RA [145]. 
 The role of p110 in RA has also been investigated. In a 
study utilising the neutrophil-dependent K/BxN serum 
transfer model of arthritis, genetic and pharmacological 
inactivation of p110 reduced joint injury. Interestingly the 
effect of pharmacological inhibition of p110 in mice with 
genetic inactivation of p110 was also assessed and was 
found to totally prevent any macroscopic evidence of joint 
inflammation or histological evidence of bone or joint 
damage. Consistent with this a marked reduction in 
neutrophil infiltration was observed, raising the possibility 
that combined p110 and p110 inhibition may potentially 
offer additive therapeutic benefits [119]. In a separate study, 
the pan-specific PI3K inhibitor ZST474 was shown to 
alleviate CIA by a mechanism that the authors suggested 
also involved the inhibition of osteoclast formation [146]. 
 Given the 70 million years of divergent evolution 
separating rodents and Homo sapiens, murine models can 
only ever reflect human disease imperfectly. Although these 
models serve a vital role in supporting the development of 
Table 3. Murine Models of PI3K Activity in RA 
 
Model Details Isoforms Studied 
CIA Markedly reduced joint inflammation Pharmacological p110 or pan-PI3K inhibition [144, 
146] 
CII-IA Markedly reduced joint inflammation, reduced neutrophil 
invasion 
Pharmacological and genetic p110 inhibition [144] 
Antigen-induced arthritis Reduced joint inflammation, reduced activation and 
migration of phagocytes 
Pharmacological and genetic p110 inhibition [147] 
K/BxN Reduced joint inflammation, particularly in dual p110 / 
p110 inhibited mice, reduced LTB4 induced neutrophil 
accumulation 
p110-/- 
p110-/- 
p110 pharmacological inhibition 
Combined p110-/-p110-/- [119] 
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isoform specific inhibitors for human use, certain 
pathophysiological differences between these models and 
human disease may be pertinent to PI3K signalling in 
particular. The CIA model, considered the most faithful 
model of human disease, shares many similarities with 
rheumatoid arthritis – an association with certain MHC Class 
II haplotypes, a breach of tolerance with generation of 
autoantibodies, and comparable clinical features. Yet the 
studies appraising p110 inhibition focussed on the effect of 
reduced neutrophil and monocyte chemotaxis. In humans 
there is evidence to suggest that retention of inflammatory 
cells within the rheumatoid joint is a more critical factor than 
the rate of synovial infiltration [148]. Furthermore neutrophil 
accumulation is a prominent feature in CIA whereas in the 
rheumatoid synovium macrophages comprise the major 
phagocytic population. Additionally, collagen autoantibodies 
are critical players in CIA pathology whilst human RA 
patients do not form autoantibodies against this antigen, and 
it is not certain that B and T cell antigen receptor signalling 
is actively engaged in established rheumatoid arthritis. 
Similar drawbacks exist with the K/BxN and serum transfer 
models of arthritis which again depend on non-RA 
autoantibodies and neutrophil infiltration [149, 150]. 
Nevertheless, murine models have been invaluable in 
supporting the progress of many recent drugs to the clinic 
and will continue to serve an essential complementary role to 
human ex vivo studies in the preclinical arena. 
 In vitro studies on human cells using p110 inhibition 
showed that T cells from healthy volunteers stimulated with 
anti-CD3 and anti-CD28 had reduced Akt phosphorylation 
and IL-17, TNF- and IFN- production. Similar results 
were found in mononuclear cells isolated from the synovial 
fluid of patients with reactive arthritis, with IFN-, TNF- 
and IL-17 production blocked to a similar extent to that 
observed with ciclosporin [71]. The effect of inhibiting PI3K 
with the broad spectrum inhibitors LY294002 and 
wortmannin has also been evaluated. PI3K was shown to be 
necessary for TGF- mediated proliferation and resistance to 
Fas-mediated apoptosis in patient synovial fibroblasts [151] 
and for the ability of anti-CD3-stimulated RA patient 
synovial T cells to induce monocyte TNF- production 
[152]. Further interest in PI3K signalling was stimulated by 
the observation that RA patient synovial fibroblasts have 
markedly reduced expression of PTEN, in keeping with over 
activity of signalling in this axis [153]. In addition, 
macrophages have PI3K-dependent expression of the pro-
survival protein Mcl-1, and LY294002 induces apoptotic 
death in RA patient synovial macrophages [154]. PI3K 
signalling is also necessary for T cell-induced IL-10 (an 
inhibitory cytokine) production by macrophages [155]. 
 Given that drugs that target innate and adaptive immune 
responses have both shown efficacy in the clinic, the 
rationale for developing dual specific p110-p110 inhibition 
in RA seems strong [156]. Studies that investigate the effect 
of isoform-specific inhibitors (both p110 and p110 
individually and together) on patient-derived samples are 
needed to combine the encouraging findings from murine 
models with the known effects of pan-PI3K inhibition seen 
in earlier studies on patient samples. 
 
 
SYSTEMIC LUPUS ERYTHEMATOSUS 
 SLE is a clinically and genetically heterogeneous 
autoimmune condition that displays a striking gender 
disparity, with females about nine times more likely to be 
affected than males. Common features include inflammatory 
arthritis, glomerulonephritis and a photosensitive rash, 
although numerous other tissues may be involved including 
the brain, lungs, heart and serosa. Significant advances in 
treatment have been achieved despite a 50 year period in 
which no new drugs were licensed for SLE. In the 1950s 
there was a 50% survival at 4 years, compared to an 80% 15 
year survival rate today [157]. However the morbidity 
associated with SLE remains substantial, with patients 
suffering recurrent disease flares necessitating potent 
immunosuppression to achieve remission. As a result, a 
patient diagnosed with SLE at the age of 20 years still has a 
1 in 6 chance of dying by the age of 35 [158]. 
 The central pathogenic process in SLE is a loss of 
tolerance to nuclear antigens [159] such as chromatin, 
ribonucleoproteins (RNP's) and DNA. This results in the 
production of autoantibodies, that subsequently give rise to 
immune complex deposition in target organs. These 
deposited immune complexes initiate complement activation 
and cross-link Fc receptors on tissue macrophages and 
plasmacytoid dendritic cells, perpetuating the inflammatory 
response. An important component of this inflammatory 
response is IFN- which promotes autoreactive T cell 
activation and B cell maturation and differentiation, resulting 
in self-perpetuating disease progression. Further actions of 
IFN- include activation of neutrophils with the release of 
neutrophil extracellular traps (NETs), a process designed to 
entrap pathogens and facilitate their killing. In SLE this 
process further exacerbates IFN- production driving disease 
flares and inflammation. 
 Current treatments are based on broadly acting 
immunosuppressants such as corticosteroids, azathioprine, 
mycophenolate and methotrexate but these drugs may be 
associated with problematic side effects. The recent approval 
by the FDA of the anti-BAFF monoclonal antibody 
belimumab for the treatment of SLE represents the first and 
only new treatment and has proven informative - not only in 
demonstrating the effectiveness of B cell targeted therapies 
but also in how to best design clinical trials for this condition 
characterised by high phenotypic heterogeneity [160, 161]. 
Initially belimumab failed at phase II to meet its co-primary 
endpoints of reduction in Safety of Estrogens in 
LupusErythematosus National Assessment–Systemic Lupus 
Erythematosus Disease Activity Index (SELENA-SLEDAI) 
score at week 24 and prolongation of time to first flare at 52 
weeks. Belimumab's eventual success depended on the 
identification of a subset of patients with seropositive SLE 
that demonstrated reduced and stabilised disease activity, 
prompting the continuation of this study  [162]. At phase III 
seropositive SLE patients randomised to belimumab 
demonstrated significantly higher SLE Responder Index 
(SRI) rates compared to placebo controls at 52 weeks and 
more had reductions of a least four points in their SELENA-
SLEDAI scores at the same time point  [160]. 
 
 
The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases The Open Rheumatology Journal, 2012, Volume 6   253 
 B cell activating factor belonging to the TNF family 
(BAFF) signalling is impaired in p110-deficient B cells, 
resulting in reduced survival, growth and proliferation in 
vitro  [63]. p110 has been found to be associated with the 
BAFF receptor, although another report suggested that the 
ability of BAFF to activate the PI3K pathway was indirectly 
mediated by an NF-B target gene  [163, 164]. Regardless of 
the precise mechanism involved, these data raise the 
possibility that one mechanism of p110 inhibitors may be to 
attenuate BAFF-dependent pathology in SLE. 
 Several genetically engineered mouse strains with 
enhanced PI3K/Akt/mTOR signalling have been noted to 
develop a lymphoproliferative syndrome with autoimmune 
features resembling SLE (Table 4) [28-30, 165-167]. 
Conversely, promising results have been obtained from 
attempts to inhibit PI3K activity in mouse models of SLE 
[168, 169]. Inhibition of p110 in the SLE-prone MRLlpr 
strain with the inhibitor AS605240 attenuated 
glomerulonephritis and extended lifespan, with 88% of 
treated mice surviving five months compared with only 60% 
of controls. Treated mice also had marked reductions in 
splenocyte numbers, lower DNA-specific autoantibody 
levels, less severe histopathological features of 
glomerulonephritis and a reduction in pathogenic CD4
+
 
memory T cells [168]. 
 In parallel experiments, the same authors used a second 
model of SLE caused by constitutive activation class 1A 
PI3K, and crossed these mice with p110 deficient mice to 
assess the ability of p110 to ameliorate lupus-like disease 
[169]. In this experimental system p110-deficient mice 
showed significantly prolonged survival with 70% still 
healthy at 16 months of age, compared with only 20% of 
SLE-prone controls, although T cell invasion and 
lymphoproliferation were unimpaired. 
 The role of p110-mediated PI3K signalling in SLE has 
not yet been directly studied in mouse models but is a 
promising area for future investigation. In San Roque mice, a 
lupus like syndrome results from the expansion of TFH cells  
 
secondary to elevated expression of the costimulatory 
receptor ICOS [170, 171]. In humans, an increased number 
of circulating TFH cells has been observed in a subset of 
patients with SLE with more severe pathology [172]. p110 
is essential for ICOS signalling and p110-deficiency 
severely impairs the development of TFH cells [64, 106]. 
Thus p110 inhibitors may provide a means of blocking the 
development or maintenance of disease-associated TFH cells 
in patients with lupus. 
 PI3K activity was found to be higher in T cells from SLE 
patients than from normal controls and this increased PI3K 
activity appeared to be provided by elevated p110 activity 
[173]. Interestingly, the PI3K activity was higher in T cells 
from patients SLEDAI scores of more than 4. The authors 
further provided evidence that the increased PI3K activity 
rendered the SLE T cells resistant to activation induced cell 
death. In a study of lipid uptake in SLE patient macrophages, 
scavenger receptor up-regulation in response to IFN- was 
blocked by inhibition of the PI3K/Akt pathway with the pan-
PI3K inhibitor LY294002 suggesting that PI3K signalling 
may contribute to foam cell formation. This could implicate 
a role for PI3K in the excess cardiovascular morbidity 
suffered by patients with SLE [174]. 
 In summary, given the central role played by PI3Ks in T 
cell-dependent humoral immune responses and B cell 
homeostasis as well as promising pre-clinical studies 
suggests a strong rationale for the development of PI3K 
inhibitors for SLE. 
OTHER AUTOIMMUNE AND INFLAMMATORY 
DISEASES 
 PI3K inhibitors have potential as treatments for a wide 
range of autoimmune and inflammatory conditions. 
Reviewing the preclinical evidence for all of these in details 
is beyond the scope of this article, but we have included a 
list of animal models in which p110 and p110 inhibitors or 
genetic knock-outs and knock-ins have shown efficacy in 
pre-clinical models in the table below (Table 5). 
 
Table 4. Murine Models of PI3K Activity in SLE 
 
Model Details Isoforms Studied 
Class 1A PI3K induced SLE (p65 regulatory subunit 
renders class 1A PI3K constitutively active, inducing SLE) 
Prolonged lifespan, reduced CD4 cell survival, 
autoantibodies and glomerulonephritis 
Genetic and pharmacological 
inhibition of p110(169) 
MRLlpr Prolonged lifespan and reduced glomerulonephritis, 
reduced lymphoid cells and autoantibodies  
Pharmacological inhibition of 
p110(168) 
 
Table 5. Other Autoimmune and Inflammatory Conditions with Preclinical Evidence for PI3K Inhibition as a Potential Treatment 
 
Model Isoforms Investigated and References 
Passive cutaneous anaphylaxis p110 [82, 83], p110 [58] 
Asthma/airway inflammation p110 [78, 147, 175-178], p110 [127, 179], dual p110 and p110 inhibition [180] 
Experimental autoimmune encephalitis  p110 [102] and p110 [109, 122] 
Atherosclerosis p110 [181] 
Contact and delayed type hypersensitivity p110 [71], p110 [59] 
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Translating the Bench-Top Science into Bedside 
Treatments 
 Selecting drugs to make the transition from preclinical 
models of diseases to effective therapies for human diseases 
remains a significant challenge. There is a substantial unmet 
need for new drugs to treat patients with RA resistant to anti-
TNF based therapies, and SLE patients intolerant of (or 
poorly responsive to) current, commonly used 
immunosuppressants. 
 The promising results from CAL-101 (the first in class 
p110 inhibitor) in its trials for refractory CLL and indolent 
non-Hodgkin's lymphoma provides some reassurance about 
the safety profile of drugs in this family [16, 17]. p110 
inhibitors are also being developed for other indications, 
including rheumatic diseases described in this review. Indeed 
a striking increase in patent applications for inhibitors 
claiming p110 selectivity has occurred over the last few 
years [182]. 
 Ongoing challenges facing the academic and 
pharmaceutical industries in the advancement of PI3K 
inhibitors include difficulties in synthesising highly specific 
p110 inhibitors [156, 183]. The availability of crystal 
structures of p110 and p110 in complex with different 
inhibitors will no doubt accelerate progress in developing 
ever more selective and potent PI3K inhibitors [21, 112]. 
Whether dual inhibitors of p110 and p110 offer advantages 
over single isoform-selective inhibitors used alone or in 
combination will need to be explored further [156]. 
 The wealth of preclinical evidence for p110 and p110 
inhibition in autoimmune and inflammatory conditions 
suggests significant potential for patient benefit. The results 
of early clinical trials are anticipated with great interest as 
the roles of these immunologically important kinases 
become more clearly defined in humans. 
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ADDENDUM 
 Since this manuscript was accepted for publication key 
papers have shown that p110 is a key regulator of 
synoviocytes function in rheumatoid arthritis. Using qPCR 
and immunohistochemistry the authors showed that p110 
mRNA and protein expression levels were higher in the 
synovial lining of patients with rheumatoid arthritis 
compared to controls with osteoarthritis. They went on to 
demonstrate that select pharmacological inhibition of p110 
could block PGDF and TNF-induced Akt activation [184]. 
Separately, the role of p110 in autoimmunity has been 
investigated using a Lyn-deficient mouse. These mice 
develop autoreactive antibodies, glomerulonephritis and 
generalised inflammation secondary to a hyperactivated B 
cell phenotype with a phenotype that has certain similarities 
to human SLE. Mice heterozygous for the p110D910A 
mutation had significantly attenuated disease parameters. 
Interestingly this protection was mediated in part as a 
consequence of greatly diminished T cell activation, despite 
the fact that Lyn is not expressed in these cells – implying an 
impairment of p110 activity restricts the ability of T cells to 
induce B cell class switching and contribute to disease [185]. 
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